<DOC>
	<DOCNO>NCT01600014</DOCNO>
	<brief_summary>The purpose study demonstrate ingenol mebutate gel efficacious treat Actinic Keratoses ( AKs ) present 8 week initial field treatment emerge previously clear field .</brief_summary>
	<brief_title>Ingenol Mebutate Gel , 0.015 % Repeat Use Multiple Actinic Keratoses Face Scalp</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subjects must provide informed consent Subjects 4 8 clinically typical , visible discrete AKs within contiguous 25 cm2 treatment area face scalp Subject least 18 year age Female subject must either : Nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus ) , Childbearing potential , provide confirm negative urine pregnancy test prior study treatment , rule pregnancy Female subject childbearing potential must willing consent use highly effective method contraception Location select treatment area : location face scalp periorbital skin within 5 cm incompletely heal wound within 10 cm suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) Prior treatment ingenol mebutate gel face scalp ( previous treatment trunk extremity acceptable ) Selected treatment area lesion atypical clinical appearance History evidence skin condition trial indication would interfere evaluation trial medication select treatment area Anticipated need hospitalization outpatient surgery prior Day 15 first treatment cycle Known sensitivity allergy ingredient ingenol mebutate gel Presence sunburn within select treatment area Current enrollment participation clinical trial within 30 day entry study Subjects previously enter first treatment trial Female subject breastfeeding Subjects institutionalise court order local authority In opinion investigator , subject unlikely comply Clinical Study Protocol Prohibited Therapies and/or Medications within 2 week prior Day 1 Cosmetic therapeutic procedure within 2 cm select treatment area Use keratolytic topical therapeutic product within 2 cm select treatment area Use topical medicate cream , ointment , lotion gel , foam spray within 2 cm select treatment area ; artificial tanner : within 5 cm select treatment area Prohibited Therapies and/or Medications : within 4 week prior Day 1 Treatment immunomodulators , cytotoxic drug interferon /interferon inducer Treatment systemic medication suppress immune system Treatment/therapy ultraviolet light A ( UVA ) ultraviolet light B ( UVB ) Prohibited Therapies and/or Medications within 8 week prior Day 1 Treatment 5fluorouracil ( 5FU ) , imiquimod , diclofenac sodium , photodynamic therapy : within 2 cm select treatment area Prohibited Therapies and/or Medications within 6 month prior Day 1 Use systemic retinoids biologic/monoclonal antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>